Financial Statements · From SEC 10-K & 10-Q XBRL Filings
Pfizer Inc. Revenue & Financial Statements
Pfizer Inc. reported revenue of $62.6B for the fiscal year ended December 31, 2025, down 1.6% year over year, with net income of $7.8B and diluted EPS of $1.36.
- Company
- Pfizer Inc. PFE · NYSE
- Latest fiscal year
- FY ended Dec 31, 2025
- Statements
- Income · Balance Sheet · Cash Flow — 5 fiscal years, 8 quarters
Income Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 81.3B | 100.3B | 50.9B | 63.6B | 62.6B |
| Cost of revenue | 30.8B | 34.3B | 25.0B | 17.9B | 16.1B |
| Gross profit | 50.5B | 66.0B | 26.0B | 45.8B | 46.5B |
| Operating income | — | — | — | — | — |
| Pretax income | 6.1B | 5.0B | (4.4B) | (637.0M) | 6.7B |
| Net income | 22.0B | 31.4B | 2.1B | 8.0B | 7.8B |
| Diluted EPS | 3.85 | 5.47 | 0.37 | 1.41 | 1.36 |
| EBITDA | — | — | — | — | — |
Quarterly
| USD | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 14.9B | 13.3B | 17.7B | 17.8B | 13.7B | 14.7B | 16.7B | 17.6B |
| Cost of revenue | 3.4B | 3.3B | 5.3B | 5.9B | 2.8B | 3.8B | 4.2B | 5.3B |
| Gross profit | 11.5B | 10.0B | 12.4B | 11.9B | 10.9B | 10.9B | 12.5B | 12.3B |
| Operating income | — | — | — | — | — | — | — | — |
| Pretax income | 3.4B | (103.0M) | 4.7B | (10.0M) | 2.8B | 3.0B | 3.3B | (1.6B) |
| Net income | 3.1B | 41.0M | 4.5B | 410.0M | 3.0B | 2.9B | 3.5B | (1.6B) |
| Diluted EPS | 0.55 | 0.01 | 0.78 | 0.07 | 0.52 | 0.51 | 0.62 | -0.29 |
| EBITDA | — | — | — | — | — | — | — | — |
Balance Sheet
Fiscal year-end snapshots. Values in USD.
| USD | FY2024 | FY2024 | FY2025 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Total assets | — | 213.4B | — | 208.2B | — |
| Current assets | — | 50.4B | — | 42.9B | — |
| Cash & equivalents | — | 1.0B | — | 1.1B | — |
| Total liabilities | — | 124.9B | — | 121.4B | — |
| Current liabilities | — | 43.0B | — | 37.0B | — |
| Long-term debt | — | 57.4B | — | 61.6B | — |
| Total debt | — | 61.2B | — | 64.6B | — |
| Stockholders’ equity | — | 88.2B | — | 86.5B | — |
| Net debt | — | 60.1B | — | 63.5B | — |
Cash Flow Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | 32.6B | 29.3B | 8.7B | 12.7B | 11.7B |
| Investing cash flow | (22.5B) | (15.8B) | (32.3B) | 2.7B | (1.4B) |
| Financing cash flow | (9.8B) | (14.8B) | 26.1B | (17.1B) | (10.3B) |
| Capital expenditure | 2.7B | 3.2B | 3.9B | 2.9B | 2.6B |
| Free cash flow | 29.9B | 26.0B | 4.8B | 9.8B | 9.1B |
| Dividends paid | — | — | — | — | — |
| Stock-based compensation | 1.2B | 872.0M | 525.0M | 877.0M | 799.0M |
Figures are parsed from SEC XBRL company facts and may be derived where issuers report year-to-date values (quarterly figures differenced; Q4 computed as FY minus Q3). Fiscal periods follow each company's fiscal calendar, not calendar years. Historical fact, not investment advice — verify with official SEC filings.
Every PFE filing, connected
Financials beside price, insider trades, and 8-K events — with alerts the moment something new is filed.